When it was approved in 2003 as the first new laser in five years, the FDA granted the ALLEGRETTO WAVE® the widest approval range ever initially given to a new laser for both myopic and hyperopic vision correction. Since then, the results have been astoundingly positive.
On gaining FDA approval in 2006, the ALLEGRETTO WAVE® Eye-Q took this tradition of excellence another step forward, providing proven superior clinical results, as shown by the following statistics:
- At one year after treatment, more than 93% of patients said they saw at least as well or better than they had with glasses or contacts before treatment.
- More than 98% of patients achieved 20/40 vision one year after treatment; 20/40 is the level of visual acuity required to pass most driving tests.
- Nearly 60% of near-sighted patients achieved 20/16 vision after one year of treatment.
- Both near- and far-sighted patients reported an improvement in their reaction to bright lights and night driving glare after ALLEGRETTO WAVE® Eye-Q treatments. In addition, near-sighted patients reported an improvement in sensitivity to light.
- Predictable results are the norm for the ALLEGRETTO WAVE® Eye-Q. More than 90% of patients achieve refraction within 1 diopter of their target correction.
A great source for information about LASIK, its risks and questions to ask your physician is the FDA website and the website of the American Society of Cataract and Refractive Surgery.